CDK inhibitors
US12285429B2 · kind B2 · utility
0Cited by
16References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 4, 2021 |
| Grant date | Apr 29, 2025 |
| Priority date | — |
| Expiry date | Jun 25, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a compound represented by the either of the following structural formulas, or a pharmaceutically acceptable salt, or a stereoisomer thereof, useful for treating cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.